INDICATIONS AND USAGE

Pneumocystis Jirovecii Pneumonia

Sevatrim is indicated in the treatment of Pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older.

Shigellosis

Sevatrim is indicated in the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei in adults and pediatric patients two months of age and older.

Urinary Tract Infections

Sevatrim is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii and Proteus species when oral administration of Sevatrim is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract.

DOSAGE

Dosage In Adults And Pediatric Patients (Two Months Of Age And Older)

The maximum recommended daily dose is 60 mL (960 mg trimethoprim) per day.

Dosage in Adults and Pediatric Patients (Two Months of Age and Older) by Indication

Pneumocystis jirovecii Pneumonia: 15-20 mg/kg (in 3 or 4 equally divided doses), Every 6 to 8 hours, for 14 days;

Severe Urinary Tract Infections: 8-10 mg/kg (in 2 to 4 equally divided doses), Every 6, 8 or 12 hours, for 14 days;

Shigellosis: 8-10 mg/kg (in 2 to 4 equally divided doses), Every 6, 8 or 12 hours, 5 days.

ADVERSE REACTIONS

Embryo-fetal Toxicity

Hypersensitivity and Other Fatal Reactions

Thrombocytopenia

Clostridium difficile-Associated Diarrhea

Sulfite Sensitivity

Risk Associated with Concurrent Use of Leucovorin for Pneumocystis jirovecii Pneumonia

Infusion Reactions

Hypoglycemia

Electrolyte Abnormalities

For full information, please refer to:

https://pillintrip.com/medicine/sevatrim

Sevatriminformation